

Daxxify® (daxibotulinumtoxinA-lanm)

When requesting Daxxify® (daxibotulinumtoxinA-lanm), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Daxxify is indicated for the treatment of cervical dystonia in adult patients.

Coverage Guidelines

Cervical Dystonia

Individual must meet the following criterion for approval:

- Is at least 18 years of age.

Approval duration: 12 months

Dosing Recommendation

The recommended dose is 125 Units to 250 Units given intramuscularly as a divided dose among affected muscles. Daxxify should be administered no more frequently than every three months.

References

1. Daxxify® injection [prescribing information]. Newark, CA: Revance; August 2023.
2. DaxibotulinumtoxinA-lanm (Daxxify®). Micromedex. Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> Accessed on April 22, 2024.
3. DaxibotulinumtoxinA-lanm (Daxxify®). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Updated; April 11, 2024; Accessed April 22, 2024.